Physician profile
Mallory Milligan
NPI 1518656404
$2,336.46
in general payments reported to CMS, 2019-2025
26 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $686 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $475.48 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.76 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $347.63 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $167.27 | 2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $161.32 | 2024-2025 | |
| Dexcom, INC. | $153.10 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $117.75 | 2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $69.98 | 2024-2025 | |
| Astellas Pharma US INC | $61.63 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $55.86 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $47.17 | 2024-2025 | Gemtesa |
| Pfizer INC. | $30.32 | 2025 | |
| Exact Sciences Corporation | $28.90 | 2025 | Cologuard Collection Kit |
| Globus Medical, INC. | $28.44 | 2025 | Senza |
| Sanofi-Aventis U.S. LLC | $24.85 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $24.83 | 2024 | Flector, Licart, Tirosint |
| Inspire Medical Systems, INC. | $24.80 | 2025 | Inspire |
| Mylan Specialty L.P. | $24.20 | 2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.00 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $19.60 | 2025 | Gvoke Hypopen |
| Aimmune Therapeutics, INC. | $18.54 | 2025 | Zenpep |
| Kowa Pharmaceuticals America, INC. | $17.57 | 2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $14.55 | 2024 | Trintellix |
| Amgen INC. | $14.29 | 2025 | Repatha |
| Axsome Therapeutics, INC. | $14.10 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.52 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Milligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.